Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors

You may be eligible if

• Histologically confirmed colorectal cancer
• Metastatic or unresectable disease OR diagnosis of solid tumor
• No known brain metastases
• ECOG 0-1 OR Karnofsky 70-100%
• Life expectancy \> 12 weeks
• Absolute neutrophil count ≥ 1,500/mm\^3
• WBC ≥ 3,000/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Bilirubin normal
• AST and ALT ≤ 3 times upper limit of normal
• Creatinine normal OR creatinine clearance ≥ 60 mL/min
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 3 months after study participation
• No ongoing or active infection
• No neuropathy \> grade 1
• No history of allergic reaction attributed to compounds of similar chemical or biological composition to study drugs
• No psychiatric illness or social situation that would preclude study compliance
• No psychiatric illness or social situation that would preclude study compliance
• No other uncontrolled illness
• Prior bevacizumab and/or cetuximab allowed
• No concurrent routine or prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF)
• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
• More than 4 weeks since prior radiotherapy
• Recovered from prior therapy
• At least 2 weeks since prior valproic acid
• No concurrent combination anti-retroviral therapy for HIV-positive patients
• No other concurrent investigational agents
• No other concurrent anticancer therapy